Alzheimer Disease
Conditions
Brief summary
The study is designed to compare the effects of 4 different doses of orally administered BI 409306 to placebo in patients with Alzheimers Disease
Interventions
DRUGBI 409306
DRUGPlacebo
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female patients with an age of at least 55 years * Body weight not lower than 50 kgs * Patients with a confirmed diagnosis of prodromal Alzheimer's Dementia (AD) on neuropsychological testing defined as: Mini-Mental State Examination (MMSE) score: greater or equal 24 and a global Clinical Dementia Rating (CDR)-score of 0 or 0.5 and Free and Cued Selective Recall Reminding Test (FCSRT) score: free recall test: lower or equal 20 (out of 48) and total recall test: lower or equal 42 (out of 48) Patients who do not reach the required score in FCSRT will additionally perform the Wechsler Memory Visual Paired Associates test. If the Wechsler Memory Visual Paired Associates test shows a cognitive deficit worse than 1 standard deviation to the mean (compared to the reference values of age and educational norms for inclusion), then the patients can be considered to be eligible for the study. * Confirmation of abnormal markers of AD pathology either via a), or alternatively b) mentioned below: 1. Presence in cerebrospinal fluid of (samples taken within past 4 months may be eligible,: low Aß1-42 concentrations (\< 640 pg/mL) and increased total tau concentrations (\> 375 pg/ml), or / and low Aß1-42 concentrations (\< 640 pg/mL) and increased phospho-tau concentrations (\> 52 pg/mL in cerebrospinal fluid), or 2. Abnormal amyloid deposition in a cerebral Positron Emission Tomography (PET) scan. Scans performed in the past according to the recommendation in the protocol are acceptable * Patients who have not received prescribed drugs for treatment of AD (including acetyl cholinesterase inhibitors (donepezil, galantamine, rivastigmine, tacrine, phenserine) and Memantine within three months prior to screening * Patients must have at least 6 years of formal education and fluency in the test language as verbally confirmed by the patient and documented by the study investigator. * Patients must have given written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to any study procedures. All patients must be able to give informed consent personally and have capacity for such consent. An informed consent given by a legal representative will not be accepted. * Patients must have a reliable study partner (per investigator judgement, for instance a family member, partner, guardian etc.)
Exclusion criteria
* Mild cognitive impairment with any etiology other than prodromal AD (for example: neurosyphilis, craniocerebral trauma, small vessel disease) based on clinical data and/or current laboratory findings and/or a pre-existing MRI or CT of the brain (CCT). If previous cranial imaging is not available or older than 12 months prior to screening then a CCT or MRI needs to be performed at screening * Substantial concomitant cerebrovascular disease (defined by a history of a stroke / intracranial haemorrhagia) temporally related to the onset of worsening of cognitive impairment per investigator judgement * Medical history of cancer (except for basal cell carcinoma) and/or treatment for cancer within the last 5 years * Medical history or diagnosis of any of symptomatic and unstable/uncontrolled conditions per investigator judgement * Severe renal impairment defined with a glomerular filtration rate (GFR) \< 30ml/min/1.73m2 in the screening central lab report * Any other psychiatric disorders such as schizophrenia, or mental retardation * Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behaviour) * Any suicidal ideation of type 4 or 5 in the Columbia Suicide Severity Rating Scale (C-SSRS) in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent) * Previous participation in investigational drug studies of mild cognitive impairment within three months prior to screening. Having received active treatment in any other study targeting disease modification like Aß immunization and tau therapies. Previous participation in studies with non-prescription medications, vitamins or other nutritional formulations is allowed. * Significant history of drug dependence or abuse (including alcohol, as defined in Diagnostic and Statistical Manual of Mental Disorders \[DSM-V\] or in the opinion of the investigator) within the last two years, or a positive urine drug screen for cocaine, heroin, or marijuana. * Known history of HIV infection * Any planned surgeries requiring general anaesthesia, or hospitalisation for more than 1 day during the study period * Pre-menopausal women (last menstruation \<= 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control * For male patients: Men who are able to father a child, unwilling to be abstinent or to use an adequate form of effective contraception for the duration of study participation and for at least 28 days after treatment has ended. * Use of any investigational drug or procedure for other indications within 3 months or 6 half-lives (whichever is longer) prior to randomization. * Intake of the following medications within 3 months prior to randomization and intended to be initiated during the duration of the trial: 1. tricyclic antidepressants, 2. antidepressants that are monoamine oxidase inhibitors, 3. neuroleptics with moderate or greater anticholinergic potency (e.g. chlorpromazine, fluphenazine, loxapine, perphenazine, thioridazine), 4. anticholinergic medications The following drugs may be given as needed if the total daily dose was stable 8 weeks prior to randomisation and is expected to be for the duration of the trial: 1. neuroleptics listed in the protocol 2. benzodiazepines and sedatives listed in the protocol * Clinically significant uncompensated hearing loss in the judgment of the investigator. Use of hearing aids is allowed. * Known hypersensitivity to the drug product excipients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | Baseline and 12 weeks | Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline |
| Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | Baseline and 12 weeks | Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | Baseline and 12 weeks | Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver. Each item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function. Least Squares Mean is actually an adjusted mean change from baseline. |
| Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | Baseline and 12 weeks | The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Each domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline. |
| Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | Baseline and 12 weeks | Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline. |
Countries
Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom, United States
Participant flow
Recruitment details
A multi-centre, double-blind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with Alzheimer's Disease
Pre-assignment details
For this trial, patients were randomised at 36 sites in 11 countries. Following an initial Screening Visit and a single blinded 2-week placebo run-in period, patients who qualified according to the in- and exclusion criteria were randomised to one of the five treatment groups
Participants by arm
| Arm | Count |
|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) Patients were administered orally a tablet of 10 mg BI 409306 once daily for 12 weeks. | 22 |
| BI 409306 25 mg QD Patients were administered orally a tablet of 25 mg BI 409306 once daily for 12 weeks. | 21 |
| BI 409306 50 mg QD Patients were administered orally a tablet of 50 mg BI 409306 once daily for 12 weeks. | 21 |
| BI 409306 25 mg Twice Daily (BID) Patients were administered orally a tablet of 25 mg BI 409306 twice daily for 12 weeks. | 21 |
| Placebo Matching BI 409306 Patients were administered orally Placebo matching 10 mg/25 mg/ 50 mg BI 409306 for 12 weeks | 43 |
| Total | 128 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 |
|---|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 0 | 0 | 0 | 1 |
| Overall Study | Other than specified | 0 | 0 | 2 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 2 | 1 | 0 |
Baseline characteristics
| Characteristic | BI 409306 10 Milligram (mg) Once Daily (QD) | Total | Placebo Matching BI 409306 | BI 409306 25 mg Twice Daily (BID) | BI 409306 50 mg QD | BI 409306 25 mg QD |
|---|---|---|---|---|---|---|
| Age, Continuous | 72.3 years STANDARD_DEVIATION 5.4 | 72.7 years STANDARD_DEVIATION 6.3 | 72.2 years STANDARD_DEVIATION 6.5 | 71.9 years STANDARD_DEVIATION 6 | 73.3 years STANDARD_DEVIATION 5.1 | 74.1 years STANDARD_DEVIATION 8.1 |
| Neuropsychological Test Battery (NTB) Total | 0.07 z-score STANDARD_DEVIATION 0.7 | -0.00 z-score STANDARD_DEVIATION 0.66 | -0.03 z-score STANDARD_DEVIATION 0.63 | -0.02 z-score STANDARD_DEVIATION 0.61 | -0.02 z-score STANDARD_DEVIATION 0.72 | 0.02 z-score STANDARD_DEVIATION 0.75 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 22 Participants | 128 Participants | 43 Participants | 21 Participants | 21 Participants | 21 Participants |
| Sex: Female, Male Female | 10 Participants | 71 Participants | 28 Participants | 13 Participants | 8 Participants | 12 Participants |
| Sex: Female, Male Male | 12 Participants | 57 Participants | 15 Participants | 8 Participants | 13 Participants | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 22 | 0 / 21 | 0 / 21 | 0 / 21 | 0 / 43 |
| other Total, other adverse events | 5 / 22 | 8 / 21 | 11 / 21 | 3 / 21 | 6 / 43 |
| serious Total, serious adverse events | 0 / 22 | 0 / 21 | 0 / 21 | 1 / 21 | 1 / 43 |
Outcome results
Primary
Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment.
Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline
Time frame: Baseline and 12 weeks
Population: The full analysis set (FAS) included all randomised patients who were treated with at least one dose of trial medication and had a baseline and at least one post-baseline on-treatment efficacy assessment. Observed cases (OC)
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.35 z-score | Standard Error 0.061 |
| BI 409306 25 mg QD | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.20 z-score | Standard Error 0.063 |
| BI 409306 50 mg QD | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.26 z-score | Standard Error 0.065 |
| BI 409306 25 mg Twice Daily (BID) | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.32 z-score | Standard Error 0.064 |
| Pooled BI 409306 | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.29 z-score | Standard Error 0.031 |
| Placebo Matching BI 409306 | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment. | 0.27 z-score | Standard Error 0.043 |
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.323695% CI: [-0.074, 0.223]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.369495% CI: [-0.22, 0.082]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.837495% CI: [-0.171, 0.139]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.548495% CI: [-0.106, 0.199]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.790595% CI: [-0.092, 0.121]Mixed Model Repeated Measurement (MMRM)
Primary
Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907)
Neuropsychological Test Battery (NTB) response, defined as change from baseline in total z-score after 12 weeks of treatment. The NTB Z-score indicates the number of standard deviations away from the mean. A Z-score of 0 is equal to the mean at baseline. Negative numbers indicate values lower than baseline and positive numbers indicate values higher than baseline. Change from baseline will be calculated as the post-baseline composite z-score minus the pre-treatment z-score, such that a positive change indicates an improvement from baseline
Time frame: Baseline and 12 weeks
Population: FAS observed cases for pooled groups of these twin trials
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.20 z-score | Standard Error 0.046 |
| BI 409306 25 mg QD | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.19 z-score | Standard Error 0.048 |
| BI 409306 50 mg QD | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.19 z-score | Standard Error 0.046 |
| BI 409306 25 mg Twice Daily (BID) | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.10 z-score | Standard Error 0.047 |
| Pooled BI 409306 | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.17 z-score | Standard Error 0.025 |
| Placebo Matching BI 409306 | Change From Baseline in Neuropsychological Test Battery in Total Z-score After 12-week Treatment From Two Twin Trials, Present 1289.5 (NCT02240693) and 1289.7 (NCT02337907) | 0.19 z-score | Standard Error 0.035 |
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.~The study identifier is also a categorical covariate for the twin studies analyses.p-value: 0.869495% CI: [-0.101, 0.12]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.~The study identifier is also a categorical covariate for the twin studies analyses.p-value: 0.951295% CI: [-0.116, 0.109]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.~The study identifier is also a categorical covariate for the twin studies analyses.p-value: 0.932195% CI: [-0.105, 0.115]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.~The study identifier is also a categorical covariate for the twin studies analyses.p-value: 0.128895% CI: [-0.199, 0.025]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, current Acetylcholine Esterase Inhibitor (AChEI) use (Yes, No), and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction. The study identifier is also a categorical covariate for the twin studies analyses.p-value: 0.649295% CI: [-0.098, 0.061]Mixed Model Repeated Measurement (MMRM)
Secondary
Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment
Alzheimer's Disease Cooperative Study/Activities of Daily Living (ADCS-ADL) is a rating scale used to assess basic and instrumental activities of daily living. In the full version of the scale, 23 items are rated by the investigator using information supplied by the caregiver. Each item has a score range varying from 0-3 to 0-5. The sum score can range from 0 to 78. Higher scores indicate better function. Least Squares Mean is actually an adjusted mean change from baseline.
Time frame: Baseline and 12 weeks
Population: FAS- Observed cases
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) | Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | 0.24 Unit on scale | Standard Error 0.896 |
| BI 409306 25 mg QD | Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | 1.79 Unit on scale | Standard Error 0.921 |
| BI 409306 50 mg QD | Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | -0.10 Unit on scale | Standard Error 0.875 |
| BI 409306 25 mg Twice Daily (BID) | Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | 0.80 Unit on scale | Standard Error 0.947 |
| Pooled BI 409306 | Change From Baseline in ADCS-MCI-ADL (Alzheimer's Disease Cooperative Study/Activities of Daily Living for Patients With Mild Cognitive Impairment) Total Score After 12-week Treatment | 0.38 Unit on scale | Standard Error 0.642 |
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.897395% CI: [-2.33, 2.04]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.214195% CI: [-0.82, 3.63]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.655395% CI: [-2.64, 1.67]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.716695% CI: [-1.85, 2.69]ANCOVA
Secondary
Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment
Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog11) is an 11-item cognitive subscale that objectively measures memory, language, orientation, and praxis with a total score range of 0 to 70. The greater the dysfunction, the greater the score. Least Squares Mean is actually an adjusted mean change from baseline.
Time frame: Baseline and 12 weeks
Population: FAS- Observed cases
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) | Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | 0.98 Unit on scale | Standard Error 0.885 |
| BI 409306 25 mg QD | Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | 0.62 Unit on scale | Standard Error 0.935 |
| BI 409306 50 mg QD | Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | 0.12 Unit on scale | Standard Error 0.875 |
| BI 409306 25 mg Twice Daily (BID) | Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | -1.27 Unit on scale | Standard Error 0.875 |
| Pooled BI 409306 | Change From Baseline in Alzheimer's Disease Assessment Scale-cognitive Subscale (ADAS-cog11) Total Score After 12-week Treatment | 1.24 Unit on scale | Standard Error 0.619 |
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.813795% CI: [-2.4, 1.89]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.580195% CI: [-2.84, 1.6]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.297895% CI: [-3.25, 1]ANCOVA
Comparison: The dependent variable was the change from the baseline score at Week 12. The model included fixed, categorical covariates of treatment as well as fixed continuous covariates of baseline score.p-value: 0.020995% CI: [-4.64, -0.39]ANCOVA
Secondary
Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment
The CDR-SB is obtained through semi-structured interviews of patients and informants, and cognitive functioning was rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Each domain was rated on a 5-point scale of functioning as follows: 0-no impairment; 0.5-questionable impairment; 1-mild impairment; 2-moderate impairment and 3-severe impairment. Only personal care was scored on a 4-point scale without a 0.5 rating available. The higher the score, the greater the severity of dementia. Least Squares Mean is actually an adjusted mean change from baseline.
Time frame: Baseline and 12 weeks
Population: FAS- Observed cases
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| BI 409306 10 Milligram (mg) Once Daily (QD) | Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | 0.0 Unit on scale | Standard Error 0.19 |
| BI 409306 25 mg QD | Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | 0.4 Unit on scale | Standard Error 0.2 |
| BI 409306 50 mg QD | Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | -0.1 Unit on scale | Standard Error 0.22 |
| BI 409306 25 mg Twice Daily (BID) | Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | 0.1 Unit on scale | Standard Error 0.21 |
| Pooled BI 409306 | Change From Baseline in Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) Total Score After 12-week Treatment | 0.1 Unit on scale | Standard Error 0.14 |
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.949195% CI: [-0.49, 0.46]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.169995% CI: [-0.15, 0.84]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.494895% CI: [-0.69, 0.33]Mixed Model Repeated Measurement (MMRM)
Comparison: Mixed Model Repeated Measurement (MMRM) includes fixed, categorical effects of treatment, visit, and treatment-by-visit interaction, as well as the continuous fixed covariates of baseline, and baseline-by-visit interaction.p-value: 0.754895% CI: [-0.42, 0.58]Mixed Model Repeated Measurement (MMRM)